Cargando…
The analysis of the long-term outcomes of sorafenib therapy in routine practice in imatinib and sunitinib resistant gastrointestinal stromal tumors (GIST)*
AIM OF THE STUDY: was to analyze the outcome of treatment and factors predicting results of sorafenib therapy in inoperable/metastatic CD117-positive GIST patients after failure on imatinib and sunitinib. MATERIAL AND METHODS: We identified 60 consecutive patients (40 men, 20 women) with advanced in...
Autores principales: | Rutkowski, Piotr, Jagielska, Beata, Andrzejuk, Jolanta, Bylina, Elzbieta, Lugowska, Iwona, Switaj, Tomasz, Kosela-Paterczyk, Hanna, Kozak, Katarzyna, Falkowski, Slawomir, Klimczak, Anna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5798420/ https://www.ncbi.nlm.nih.gov/pubmed/29416434 http://dx.doi.org/10.5114/wo.2017.72393 |
Ejemplares similares
-
The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study
por: Rutkowski, Piotr, et al.
Publicado: (2012) -
Age as a Prognostic Factor in Patients with Ewing Sarcoma—The Polish Sarcoma Group Experience
por: Jagodzińska-Mucha, Paulina, et al.
Publicado: (2021) -
The Long-Term Outcomes of Intensive Combined Therapy of Adult Patients with Localised Synovial Sarcoma
por: Kozak, Katarzyna, et al.
Publicado: (2020) -
Trametinib: a MEK inhibitor for management of metastatic melanoma
por: Lugowska, Iwona, et al.
Publicado: (2015) -
Immune checkpoint inhibitors therapy in older patients (≥ 70 years) with metastatic melanoma: a multicentre study
por: Cybulska-Stopa, Bożena, et al.
Publicado: (2019)